fda changes to semaglutide 🚨 Moves Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like and tirzepatide, signaling a major shift in how these FDA's Removal of Semaglutide and

Improving medication adherence among patients with type 2 diabetes

This means it simultaneously activates three key receptors: GLP-1 (Glucagon-Like Peptide-1) involved in reducing appetite, slowing digestion, and improving insulin secretion

Oxidative Stress and Neuroprotection Sviridov, I

A total of 50 participants (men and women, 3560 years of age) with dry skin, skin moisture content of 49% or less, or crows feet greater than grade 3 were tested for 12 weeks in this double-blind, randomized, parallel, placebo-controlled study (equal numbers of subjects were in the APCP or placebo groups)

Consistent with this, boosting shuttle activity (via overexpression of their enzymes) decreased lactate accumulation and diverted more glucose into citrate with no impairment of proliferation 186 , also in agreement with an earlier notion that the Warburg effect is a consequence of limited NADH-shuttle throughput rather than a driver of proliferation 187